Full Breakdown
Trump Administration Extends MFN Drug Pricing to All Medicaid Programs
By Drooid · · How we work
Core Event: Nationwide MFN Pricing Rollout
On September 18, the Trump administration announced that every state Medicaid program, the District of Columbia and Puerto Rico will participate in a “most-favored-nation” (MFN) pricing model for selected prescription drugs. The rollout, branded the “GENEROUS” model, expands earlier voluntary agreements with pharmaceutical manufacturers to a nationwide pilot.
Background & Context
President Donald J. Trump introduced an MFN policy through an executive order last year, pledging to align U.S. drug prices with the lowest prices paid by other affluent nations. By the September 18 announcement, the White House said 26 of the world’s largest drugmakers—covering roughly 90 % of the branded U.S. market—had signed agreements.
Data & Statistics
- Companies involved: 26 manufacturers, representing about 90 % of the U.S. branded market.
- Projected savings: Estimates range from $64 billion in state Medicaid savings to over $600 billion over a decade; a May internal estimate mentioned $529 billion over ten years.
- State-level impact: Mississippi’s governor noted $700 million spent annually on Medicaid drugs.
- Program scope: The pilot aims to cover “hundreds of millions” of dollars in drug costs, with early reports of $700 million in savings already returned to patients through the TrumpRx portal.
Official Statements & Responses
President Trump framed the expansion as an election-winning achievement, asserting that the MFN model will let states redirect billions toward other health services. Health and Human Services Secretary Robert F. Kennedy Jr. said the savings would break a “negative feedback loop” that forces families to choose between medication and basic needs. Administration officials described the MFN approach as a way for states to obtain “fairer, more competitive pricing” without altering existing Medicaid coverage rules.
On-the-Ground Reports
The MFN program operates as a voluntary pilot. States must formally opt in and accept standardized pricing terms, which may override existing prior-authorization or step-therapy rules. Massachusetts announced participation; California indicated it would apply pending further details. Deadline submissions were originally set for spring and summer 2026 but have been pushed back, prompting criticism from health-policy experts.
Conflicting Reports & Gaps
- Savings estimates vary widely: $64 billion, $529 billion, and “more than $600 billion.”
- Drug coverage scope remains opaque; the administration has not released the full list of discounted products, and several companies declined to confirm which medicines are included.
- Program status: While the White House claims a historic price drop, independent analysis notes that Medicaid already receives steep discounts, making the incremental effect uncertain.
Verbatim Quotes
- “This one thing alone should win us the midterms,” — Donald Trump
- “Companies have every incentive to cherry-pick [for this program] the products for which they already give Medicaid the best discounts and for which the international price may not be that much lower,” — Dr. Thomas Hwang
- “It's always a bad sign when you keep pushing back your deadline,” — Ameet Sarpatwari
What’s Next
State applications continue after the missed September 10 deadline, and lawmakers are debating whether to codify the MFN arrangements into permanent legislation. The administration indicated that additional pharmaceutical companies may be invited to join the pilot, but no timeline has been disclosed.